OrbiMed | Jotup

Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed

Retrieved on:

星期三, 七月 26, 2023

Agreement, SOFR, Dermatology, FDA, Therapy, OrbiMed, TD, Skin, Pharmaceutical industry

WEST CHESTER, Pa., July 26, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the closing of the previously announced $125 million debt financing with OrbiMed (“the Agreement”), a leading healthcare investment firm.

Key Points:

Under the terms of the Agreement, Verrica borrowed $50 million at the close of the transaction.
The facility is a five-year term loan that matures in July 2028.
Verrica also issued to OrbiMed a warrant to purchase 518,551 shares of the Company’s common stock, with an exercise price of $6.0264.
TD Cowen served as exclusive financial advisor to Verrica on this transaction.

Global Lysine Research Report 2023-2028: Growing Healthcare Awareness Drives Demand - Nutrient-Rich Food and Medicinal Value Boost Market Prospects

Retrieved on:

星期三, 七月 26, 2023

The market is being driven by increasing demand in various end-user industries, including animal feed, food, and healthcare.

Key Points:

The market is being driven by increasing demand in various end-user industries, including animal feed, food, and healthcare.
Factors such as growing meat consumption, expansion of the cattle industry, and rising demand for functional food ingredients are contributing to the market's revenue growth.
Moreover, significant investments in research and development activities to enhance production capacity further bolster the market's prospects.
The growing global population, coupled with the increasing consumption of meat, is expected to drive the growth of global lysine market.

The Silverstein Foundation Launches Post-Doctoral Fellowship Program to Fund Novel Research for Parkinson’s Disease in GBA Mutation Carriers

Retrieved on:

星期四, 七月 20, 2023

The Silverstein Foundation for Parkinson’s with GBA (“Silverstein Foundation”) today announced the creation of a two-year, post-doctoral fellowship program that will fund eleven scientists engaged in cutting-edge research on Parkinson’s disease in GBA mutation carriers (GBA-PD) in academic and hospital-based laboratories around the world.

Key Points:

The Silverstein Foundation for Parkinson’s with GBA (“Silverstein Foundation”) today announced the creation of a two-year, post-doctoral fellowship program that will fund eleven scientists engaged in cutting-edge research on Parkinson’s disease in GBA mutation carriers (GBA-PD) in academic and hospital-based laboratories around the world.
“The goal of this two-year program is to fund the next generation of elite researchers who will devote their time to finding novel, diverse approaches to analyze, prevent and treat GBA-PD,” said Jonathan Silverstein, founder of the Silverstein Foundation and a retired Managing Partner and former Co-Head of Private Equity at OrbiMed.
Silverstein added, “These researchers will meet regularly to collaborate and share findings with each other.
Furthermore, these findings will be made public to the broader GBA-PD community through publications and presentations at scientific conferences worldwide.

LSI USA Emerging Medtech Summit Returns to Dana Point March 18, 2024

Retrieved on:

星期二, 六月 13, 2023

HUNTINGTON BEACH, Calif., June 13, 2023 /PRNewswire/ -- LSI, the company behind LSI Emerging Medtech Summits, the partnering events for global leaders building breakthrough healthcare businesses, today announced it will host its next USA Emerging Medtech Summit, LSI USA '24, on March 18 through 22 at the Monarch Beach Resort, Waldorf Astoria in Dana Point, California.

Key Points:

HUNTINGTON BEACH, Calif., June 13, 2023 /PRNewswire/ -- LSI, the company behind LSI Emerging Medtech Summits, the partnering events for global leaders building breakthrough healthcare businesses, today announced it will host its next USA Emerging Medtech Summit, LSI USA '24, on March 18 through 22 at the Monarch Beach Resort, Waldorf Astoria in Dana Point, California.
Designed to facilitate partnerships between innovators, investors, and strategics in medtech and healthcare, the four-day event will spotlight the emerging topics, trends, and insights that are moving the industry forward.
"LSI USA '24 will truly serve as the epicenter of our industry, bringing together the most influential leaders to tackle medtech's largest challenges and rally around its emerging opportunities," said Scott Pantel, Founder & CEO of LSI.
The LSI USA Emerging Medtech Summit, which celebrates its fifth year, has quickly become the epicenter of medtech and healthcare technology innovation.

Upstream Bio Announces $200M Series B Financing to Advance UPB-101 for Allergic and Inflammatory Diseases

Retrieved on:

星期四, 六月 8, 2023

Upstream Bio , a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the completion of a $200 million Series B financing.

Key Points:

Upstream Bio , a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the completion of a $200 million Series B financing.
Upstream will pursue registrational Phase 2 clinical trials in asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) thereafter.
“Enavate is thrilled to be co-leading this important investment in Upstream Bio to advance the clinical development of UPB-101.
Edd Fleming of Enavate Sciences and Alex Rosen of Venrock Healthcare Capital Partners have joined the Board of Directors of Upstream Bio.

X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market

Retrieved on:

星期二, 五月 16, 2023

Therapy, Stifel, OrbiMed, WHIM, PIPE, Exchange, Sale, Adage Capital Management, NEA, WHIM syndrome, Immune system, Webcast, Security (finance), Rare, New Enterprise Associates, Safety, Pharmaceutical industry

X4 anticipates that gross proceeds from the PIPE will be approximately $65 million, before deducting fees to the placement agents and other estimated offering expenses payable by the Company.

Key Points:

X4 anticipates that gross proceeds from the PIPE will be approximately $65 million, before deducting fees to the placement agents and other estimated offering expenses payable by the Company.
The closing of the financing is expected to occur on or about May 18, 2023, subject to customary closing conditions.
The webcast can also be accessed on the investor relations section of X4’s website at www.x4pharma.com.
X4 expects to use these funds for continued clinical development and commercial readiness of its lead candidate, mavorixafor, and for working capital, and general corporate purposes.

InspireMD Announces Private Placement of Up to $113.6 Million

Retrieved on:

星期一, 五月 15, 2023

TCAR, OrbiMed, Stroke, Velan, NPS, TEL, NSPR, CAS, EPS, Pharmaceutical industry, Soleus muscle

TEL AVIV, Israel and MIAMI, May 15, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the Company has signed a securities purchase agreement with certain healthcare-focused institutional investors that have agreed to provide up to $113.6 million in gross proceeds to InspireMD through a private placement that includes initial upfront funding of $42.2 million. The financing is being led by Marshall Wace with participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members.

Key Points:

Led by Marshall Wace with participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members
TEL AVIV, Israel and MIAMI, May 15, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the Company has signed a securities purchase agreement with certain healthcare-focused institutional investors that have agreed to provide up to $113.6 million in gross proceeds to InspireMD through a private placement that includes initial upfront funding of $42.2 million.
The financing is being led by Marshall Wace with participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members.
“We are very pleased to have achieved this important milestone with leading fundamental healthcare investors who have chosen to participate in this transformational financing of our company,” stated Marvin Slosman, chief executive officer of InspireMD.
“Advancing our growing product pipeline, including our new CGuard Prime Transfemoral (CAS) delivery system along with our SwitchGuard trans carotid (TCAR) neuroprotection system (NPS), positions our company to serve the entire carotid revascularization market, continuing our mission of delivering implant focused patient outcomes.”

BiomX Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on:

星期一, 五月 15, 2023

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 15, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the first quarter ended March 31, 2023.

Key Points:

and NESS ZIONA, Israel, May 15, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the first quarter ended March 31, 2023.
We expect to report results from Part 2 in the third quarter of 2023.
Results from Part 2 of the trial are expected in the third quarter of 2023.
BiomX management will host a conference call and webcast today at 8:00 am ET to report financial results and business updates for the first quarter of 2023.

Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on:

星期一, 五月 15, 2023

Interim data will be presented at EHA Congress on June 9, 2023, with an accompanying management call at 7:30 am ET the same day.

Key Points:

Interim data will be presented at EHA Congress on June 9, 2023, with an accompanying management call at 7:30 am ET the same day.
Announced a collaboration with NIH to study bitopertin in patients with Diamond-Blackfan Anemia in March 2023; the study is expected to initiate mid-year 2023.
First Quarter 2023 Financial Results:
Cash Position: Cash and cash equivalents were $236.4 million as of March 31, 2023 compared to $194.6 million as of December 31, 2022.
Net Loss: The net loss was $22.8 million for the first quarter of 2023, as compared to $9.9 million for the first quarter of 2022.

BiomX Announces Second Closing of $7.5 Million Private Placement

Retrieved on:

星期五, 五月 5, 2023

OrbiMed, PIPE, Urinary tract infection, Cystic fibrosis, Sale, Patient, NESS, Cystic Fibrosis Foundation, SPA, NYSE American, Security (finance), NYSE, Pharmaceutical industry

and NESS ZIONA, Israel, May 05, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the second closing of its recently announced $7.5 million private placement (“PIPE”) investment.

Key Points:

and NESS ZIONA, Israel, May 05, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the second closing of its recently announced $7.5 million private placement (“PIPE”) investment.
The second closing announced today was contingent upon approval of the issuance of the additional securities under the SPA by the Company's stockholders in accordance with NYSE American rules.
Pursuant to the SPA, at the second closing, the Company issued 24,632,243 shares of common stock (or common stock equivalents, the “Securities”) for gross proceeds of approximately $6 million, at a price of $0.245 per share.
BiomX and the investors have also entered into a Registration Rights Agreement pursuant to which BiomX has agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) registering the resale of the securities sold in the PIPE within 30 days following the second closing.